PolyNovo is focused on advancing patient care through its innovative NovoSorb technology, which is designed to enhance natural healing processes. This technology is particularly significant in the field of wound care and tissue regeneration, as it provides a scaffold that supports the growth of new tissue while minimizing complications associated with traditional methods. NovoSorb is engineered to be biocompatible and biodegradable, allowing it to integrate seamlessly with the body and promote effective healing outcomes.

The company offers a range of products utilizing NovoSorb technology, including NovoSorb BTM (Biodegradable Temporizing Matrix) and NovoSorb MTX, which are specifically designed for various clinical applications. These products aim to redefine the standard of care in surgical and wound management by providing solutions that not only facilitate healing but also improve overall patient outcomes. PolyNovo's commitment to innovation is reflected in its ongoing research and development efforts, as well as its focus on delivering effective solutions for healthcare professionals and patients alike.

Australia

PolyNovo is a disruptive ASX 200 medical technology company. Its products simplify managing acute complex wounds, redefining healing with differentiated outcomes across many etiologies. After treating 50,000+ patients across 42 countries, the company is investing for growth via new products, indications and markets with a view to treat millions more.  

Our registered address is 2/320 Lorimer St, Port Melbourne, Victoria 3207, Australia.

PolyNovo

Company Details